US Markets

Legend names founder Frank Zhang as chief executive officer

Legend Biotech Corp, a cell therapy unit of Hong Kong-listed Genscript Biotech Corp, said on Sunday it appointed Frank Zhang as chief executive officer and that he will step down as Genscript's CEO.

Aug 2 (Reuters) - Legend Biotech Corp LEGN.O, a cell therapy unit of Hong Kong-listed Genscript Biotech Corp 1548.HK, said on Sunday it appointed Frank Zhang as chief executive officer and that he will step down as Genscript's CEO.

Outgoing Legend CEO Yuan Xu resigned for personal reasons, according to the U.S.-based Biotech firm, adding that Xu also resigned from Legend's board.

Zhang, who founded Legend in 2014, has been the board chairman for past five years. He will continue in the position and take charge as CEO effective immediately.

The leadership change came about two months after the firm's U.S. stock market debut. Legend raised $423.8 million in the initial public offering.

(Reporting by Maria Ponnezhath in Bengaluru; Editing by Steve Orlofsky)

((Maria.Ponnezhath@thomsonreuters.com; +91 8061822749;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

LEGN

Latest Markets Videos

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More